Donanemab slows Alzheimer’s disease in trial, but with serious side effects
New Scientist - 18-Jul-2023New Alzheimer's drug benefits early-stage patients; concern remain about affordability and serious risks
Join the club for FREE to access the whole archive and other member benefits.
Senior Vice President and Chief Scientific Officer, Eli Lilly and Company
Dan Skovronsky is the chief scientific officer of Eli Lilly and Company. He serves as senior vice president of science and technology and president of Lilly Research Laboratories. Dan joined Lilly in 2010 when the company acquired Avid Radiopharmaceuticals Inc., where he had been CEO since founding the company in 2004. At Lilly, Dan has held various roles, including vice president, tailored therapeutics; vice president, diabetes research; and most recently, senior vice president, clinical and product development.
Dan completed his residency training in pathology and fellowship training in neuropathology at the Hospital of the University of Pennsylvania. He received his M.D. from the Perelman School of Medicine, University of Pennsylvania, in 2001 and his Ph.D. in Neuroscience from University of Pennsylvania in 2000. Dan earned a Bachelor of Science in molecular biophysics and biochemistry from Yale University in 1994.
Visit website: https://www.lilly.com/leadership/executive-committee/daniel-skovronsky
See also: Eli Lilly and Company - American pharmaceutical company
Details last updated 13-Jan-2021
New Alzheimer's drug benefits early-stage patients; concern remain about affordability and serious risks
Clears plaque and slows clinical decline in patients with early-stage Alzheimer's